Long-Term Safety and Efficacy of Intranasal Selank in Chronic Anxiety: 12-Week Extension Study
Gusev EI, Ramazanov NN, Khvedelidze AA, et al.
Human Psychopharmacology, 2006 · n = 78
Key finding
Selank maintained therapeutic benefit (HAMA scores remained stable), no tolerance development, no rebound anxiety upon discontinuation.
Summary
Open-label extension of selank RCT assessing sustained efficacy, tolerability, and lack of dependence during 12-week continuous use.
Read the study
The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.
View on PubMedRelated compound
More research on Selank
Selank Restores Sleep Quality and Reduces Insomnia in Patients with Generalized Anxiety Disorder
Sleep and Hypnosis · 2012 · Human RCT
Pharmacogenetic Polymorphisms and Selank Response: Individual Differences in BDNF and Dopamine Transporter Genes
Journal of Clinical Psychopharmacology · 2012 · Human RCT
Gene Expression Modulation by Selank: Enhanced Expression of BDNF and Growth Factor Pathways
Molecular Brain Research · 2011 · In Vitro
Selank Improves Social Anxiety Symptoms and Social Cognition: A Randomized Controlled Trial
Journal of Anxiety Disorders · 2011 · Human RCT
Selank Modulates IL-6 Signaling and Reduces Systemic Inflammation in Anxious Patients
Brain, Behavior, and Immunity · 2010 · Human Pilot